Related Experiment Video
Updated: Jul 28, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
OnabotulinumtoxinA for Pediatric Migraine
Victoria Karian1, Hannah Morton1, Zoë J Schefter1
1Pediatric Headache Program, Division of Pain Medicine, Department of Anesthesiology, Perioperative & Pain Medicine, Boston Children's Hospital, Boston, Massachusetts.
Summary
OnabotulinumtoxinA (BTX-A) effectively reduced headache frequency and severity in pediatric patients with chronic migraine. This treatment offers a safe option for children, improving their quality of life.
Area of Science:
- Pediatric Neurology
- Clinical Therapeutics
- Pain Management
Background:
- Migraine significantly impacts children's well-being, necessitating safe and effective treatments.
- Access to appropriate therapies is crucial for managing this chronic condition in pediatric populations.
Purpose of the Study:
- To evaluate the experiences, effects, and clinical response of adolescents to onabotulinumtoxinA (BTX-A) for migraine prevention.
- To assess the safety and efficacy of BTX-A in managing chronic migraine in children aged 13-17.
Main Methods:
- Retrospective review of clinical data for 32 pediatric patients (13-17 years) treated with BTX-A for chronic migraine (2016-2022).
- Analysis of variance (ANOVA) used to compare headache frequency, severity, and duration at baseline and after BTX-A injections.
Main Results:
- BTX-A treatment led to a significant decrease in headache frequency and severity.
- Participants experienced approximately seven fewer headache days per month post-treatment.
- Reported side effects included neck stiffness, flu-like symptoms, fatigue, and temporary pain worsening.
Conclusions:
- OnabotulinumtoxinA (BTX-A) is a safe and effective treatment option for pediatric migraine.
- BTX-A can significantly reduce the burden of chronic migraine on children's physical, emotional, and mental health.
- Nurses play a vital role in advocating for and educating patients about BTX-A for pediatric migraine management.
More Related Videos
Related Concept Videos
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...